A new startup incubator to develop biotechnology and other healthcare companies in the United States, the UK and Africa plans an initial public offering next month.
Dublin-based Malin expects to raise as much as €325m from a listing on the Dublin stock exchange's Enterprise Securities Market, the company said yesterday.
The newly-formed company will also provide management expertise to help develop ten to 12 companies, chief executive Adrian Howd said in an interview.
Malin board members include former Elan chief executive Kelly Martin and former Glaxo Wellcome boss Robert Ingram.
Malin joins an effort from investor Neil Woodford, who started a £200m investment trust earlier this month to back UK companies with high-growth potential.
"Investor appetite for biotech has never been better, given the research and development successes over the last 18 months," Mr Howd said.
"There is so much opportunity, but a lot of good science can go to waste with poor execution."
Malin plans to pre-empt such failures by providing guidance through board seats and other management roles at its portfolio companies.
The group's executives will help develop products and prepare the startups for options such as public listings and trade sales.
The first companies Malin will work with include Kymab, based in Cambridge, England, which is developing cancer immunotherapies.
Malin will also work with Serenus Biotherapeutics, a distributor of medicines across Africa, and Xenex Disinfection Services in San Antonio, Texas, a maker of germ-zapping robots that disinfect hospital rooms.